Logo

sepsis

Immunexpress Receives FDA 510(k) Clearance for Sepsis Assay

The assay, which runs on the company's Idylla platform, distinguishes sepsis from noninfectious systemic inflammation.

T2 Biosystems Q3 Revenues Jump 42 Percent

The firm sold eight T2Dx instruments in the quarter, including two in Asia where it has also entered contracts to sell four more in Q4.

BARDA Exercises $6.4M Option on T2 Biosystems Contract

The funding supports development of antimicrobial resistance, biothreat agent, and sepsis pathogen panels, as well as a next-gen instrument.

UK Startup Presymptom Health Developing Host-Response Prognostic Test for Sepsis
Premium

The firm recently kicked off a study to determine whether a set of RNA-expression biomarkers can provide a high negative predictive value to rule out sepsis.

T2 Biosystems Q2 Revenues More Than Double, Beat Estimates

The firm sold three T2Dx instruments in the quarter and saw an annualized run rate of sepsis tests of $98,000 per legacy instrument.

May 20, 2021

With Finder Platform, Baebies Works to Expand Options for Neonatal Dx Testing
Premium

May 7, 2021

T2 Biosystems Advancing Pipeline, Accelerating Instrument Placement Strategy
Premium

Apr 27, 2021

CARB-X Awards GenomeKey Up to $9.5M to Develop Rapid Diagnostic Test for Sepsis

Apr 20, 2021

Baebies Awarded up to $11.6M in CARB-X Funding for Neonatal Sepsis Test

Mar 16, 2021

Inflammatix Raises $102M in Series D Financing to Continue Development of Immune-Response Tests

Mar 4, 2021

T2 Biosystems Q4 Revenues Jump 152 Percent on Strong Product Sales

Feb 26, 2021

GenMark Diagnostics Seeing Continued Demand for Respiratory Panels, Plans 510(k) Submission
Premium

Jan 27, 2021

T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates

Jan 21, 2021

Molzym, Fraunhofer Developing Rapid Direct-From-Sample Sepsis Diagnostic Platform and Test
Premium

Nov 4, 2020

T2 Biosystems Q3 Revenues Triple, Beat Estimates

Nov 4, 2020

Biocartis to Invest in IVD Partnerships Following Termination of Genomic Health Deal
Premium

Nov 3, 2020

Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform

Oct 15, 2020

Scanogen Developing Direct-From-Blood Infection Test That Could Provide Results in 90 Minutes
Premium

Oct 8, 2020

Inflammatix Moving Into Coronavirus Test Market With Gene Expression Host Response Platform
Premium

Sep 1, 2020

Immunexpress, Biocartis to Roll Out Sepsis Test in Europe Ahead of Planned US Launch
Premium

Aug 13, 2020

HelixBind Aims to Circumvent Culture With Rapid Technology to Detect Bloodstream Infections
Premium

Aug 11, 2020

T2 Biosystems Q2 Revenues Up 41 Percent, Beat Estimates

Jul 20, 2020

Sepset Biosciences Leveraging COVID-19 Patient Samples in Study to Validate Sepsis Test
Premium

Jul 1, 2020

T2 Biosystems Preliminary Q2 Revenues Up About 40 Percent; Firm Launches COVID-19 Test

Jun 16, 2020

Immunexpress Nabs $599K BARDA Contract to Develop Sepsis Test for Coronavirus Patient Triage

Breaking News
The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.